Management of Interferon-β1b (Betaseron) Failures in Multiple Sclerosis with Interferon-αn3 (Alferon N)
The introduction of interferon-β1b (IFN-β1b, Betaseron) in 1993 heralded a new era in the management of multiple sclerosis (MS). A modest overall reduction of exacerbations of 33.8% was enhanced by a 47% reduction for “moderately severe and severe exacerbations”, as defined in the protocol . Adverse experience with IFN-β1b, however, was encountered in the majority of trial participants, as well as in the clinical setting [1, 2].
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Hairy Cell Leukemia Adverse Experience Cutaneous Ulceration
Unable to display preview. Download preview PDF.
- 5.Paty DW, Hartung HP, Ebers GC et al (1999) Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur Neurol 6 [Suppl 1]:S1–S35Google Scholar
- 6.Di Paola M, Ogin E, Smith Y et al (1992) Interferon-a subtypes in natural human leukocyte interferon (interferonα-n3). J Interferon Res 12:5318Google Scholar
- 8.Sheremata W, Minagar A, Whiteman M, Onufer J (2001) Interferon-alfa-n3 (Alferon N) reduces gadolinium enhancing brain lesions in multiple sclerosis. J Neurosci 187 [Suppl 1] S454Google Scholar